Logo - springer
Slogan - springer

Medicine - Oncology & Hematology | Biosimilars - A New Generation of Biologics

Biosimilars

A New Generation of Biologics

Prugnaud, Jean-Louis, Trouvin, Jean-Hugues (Eds.)

Original French edition published by Springer-Verlag, Paris, 2011

2012, XVIII, 90 p.

Available Formats:
eBook
Information

Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.

You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.

After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.

 
$109.00

(net) price for USA

ISBN 978-2-8178-0336-4

digitally watermarked, no DRM

Included Format: PDF and EPUB

download immediately after purchase


learn more about Springer eBooks

add to marked items

Hardcover
Information

Hardcover version

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
$139.00

(net) price for USA

ISBN 978-2-8178-0335-7

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days


add to marked items

Softcover
Information

Softcover (also known as softback) version.

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
$139.00

(net) price for USA

ISBN 978-2-8178-0514-6

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days


add to marked items

  • Analysis of the complete legal and regulatory framework
  • Approach of the context of copies of biology and biotechnology drugs
  • Details the registration conditions
  • Analysis of these drugs’ marketing (drug safety, prices and distribution channels, substitution and interchangeability…)
  • Investments’ costs and returns on investments are also pointed out
  • A section is focused on the US approach

Biologics have revolutionised the treatment of many severe conditions, delivering exceptional clinical results but also producing exceptionally high prices. As patents expire, copies and price competition are expected throughout the world. However, due to the intrinsic heterogeneity and molecular complexity of biologic medicinal products, their copies cannot simply be authorized under the “generic rule” valid for small chemical entities.

 

In response, a dedicated regulation was issued in the European Union. It is based on the concept of “biological medicinal products similar to a biological reference product”, or “biosimilars”. This book analyses the context of biotechnological production and addresses the European legal framework for biosimilar market approval. It highlights post-market authorisation issues, such as Risk Management Plans and substitution of products, and outlines some other issues, such as cost management and international nomenclature.

 

This book is primarily intended for hospital-based physicians and pharmacists. It will also be a valuable resource for all actors from all countries who want to better understand the emergence of these new medicinal products within the European context.

Content Level » Professional/practitioner

Keywords » Biomedicine - Biosimilars - Cost - Immunogenicity - Interchangeability

Related subjects » Immunology - Nephrology - Oncology & Hematology - Pharmacology & Toxicology

Table of contents / Preface / Sample pages 

Popular Content within this publication 

 

Articles

Read this Book on Springerlink

Services for this book

New Book Alert

Get alerted on new Springer publications in the subject area of Oncology.